These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

731 related items for PubMed ID: 15598707

  • 21. Lefunomide in combination therapy.
    Kalden JR, Smolen JS, Emery P, van Riel PL, Dougados M, Strand CV, Breedveld FC.
    J Rheumatol Suppl; 2004 Jun; 71():25-30. PubMed ID: 15170905
    [Abstract] [Full Text] [Related]

  • 22. Infliximab therapy in established rheumatoid arthritis: an observational study.
    Voulgari PV, Alamanos Y, Nikas SN, Bougias DV, Temekonidis TI, Drosos AA.
    Am J Med; 2005 May; 118(5):515-20. PubMed ID: 15866254
    [Abstract] [Full Text] [Related]

  • 23. The effect of infliximab and timing of vaccination on the humoral response to influenza vaccination in patients with rheumatoid arthritis and ankylosing spondylitis.
    Elkayam O, Bashkin A, Mandelboim M, Litinsky I, Comaheshter D, Levartovsky D, Mendelson E, Wigler I, Caspi D, Paran D.
    Semin Arthritis Rheum; 2010 Jun; 39(6):442-7. PubMed ID: 19246078
    [Abstract] [Full Text] [Related]

  • 24. Sustained effect after lowering high-dose infliximab in patients with rheumatoid arthritis: a prospective dose titration study.
    van den Bemt BJ, den Broeder AA, Snijders GF, Hekster YA, van Riel PL, Benraad B, Wolbink GJ, van den Hoogen FH.
    Ann Rheum Dis; 2008 Dec; 67(12):1697-701. PubMed ID: 18245109
    [Abstract] [Full Text] [Related]

  • 25. Infliximab treatment in patients with rheumatoid arthritis and spondyloarthropathies in clinical practice: adverse events and other reasons for discontinuation of treatment.
    Levälampi T, Korpela M, Vuolteenaho K, Moilanen E.
    Scand J Rheumatol; 2008 Dec; 37(1):6-12. PubMed ID: 18189188
    [Abstract] [Full Text] [Related]

  • 26. Comparison of rheumatoid arthritis care costs in patients starting therapy with leflunomide versus etanercept.
    Yazdani C, McLaughlin T, Cummins G, Doyle J.
    Am J Manag Care; 2001 Sep; 7(13 Suppl):S419-26. PubMed ID: 11594238
    [Abstract] [Full Text] [Related]

  • 27. Combination leflunomide and methotrexate (MTX) therapy for patients with active rheumatoid arthritis failing MTX monotherapy: open-label extension of a randomized, double-blind, placebo controlled trial.
    Kremer J, Genovese M, Cannon GW, Caldwell J, Cush J, Furst DE, Luggen M, Keystone E, Bathon J, Kavanaugh A, Ruderman E, Coleman P, Curtis D, Kopp E, Kantor S, Weisman M, Waltuck J, Lindsley HB, Markenson J, Crawford B, Fernando I, Simpson K, Strand V.
    J Rheumatol; 2004 Aug; 31(8):1521-31. PubMed ID: 15290730
    [Abstract] [Full Text] [Related]

  • 28. Leflunomide, a new disease-modifying drug for treating active rheumatoid arthritis in methotrexate-controlled phase II clinical trial.
    Bao C, Chen S, Gu Y, Lao Z, Ni L, Yu Q, Xu J, Li X, Liu J, Sun L, He P, Ma J, Xu S, Ding C.
    Chin Med J (Engl); 2003 Aug; 116(8):1228-34. PubMed ID: 12935395
    [Abstract] [Full Text] [Related]

  • 29. Combination treatment with leflunomide and methotrexate for patients with active rheumatoid arthritis.
    Lee SS, Park YW, Park JJ, Kang YM, Nam EJ, Kim SI, Lee JH, Yoo WH, Lee SI.
    Scand J Rheumatol; 2009 Aug; 38(1):11-4. PubMed ID: 19191187
    [Abstract] [Full Text] [Related]

  • 30. Efficacy and safety of leflunomide 10 mg versus 20 mg once daily in patients with active rheumatoid arthritis: multinational double-blind, randomized trial.
    Poór G, Strand V, Leflunomide Multinational Study Group.
    Rheumatology (Oxford); 2004 Jun; 43(6):744-9. PubMed ID: 15026583
    [Abstract] [Full Text] [Related]

  • 31. Long-term open-label preliminary study of the safety and efficacy of leflunomide in patients with polyarticular-course juvenile rheumatoid arthritis.
    Silverman E, Spiegel L, Hawkins D, Petty R, Goldsmith D, Schanberg L, Duffy C, Howard P, Strand V.
    Arthritis Rheum; 2005 Feb; 52(2):554-62. PubMed ID: 15693001
    [Abstract] [Full Text] [Related]

  • 32. Adjunctive anakinra in patients with active rheumatoid arthritis despite methotrexate, or leflunomide, or cyclosporin-A monotherapy: a 48-week, comparative, prospective study.
    Karanikolas G, Charalambopoulos D, Vaiopoulos G, Andrianakos A, Rapti A, Karras D, Kaskani E, Sfikakis PP.
    Rheumatology (Oxford); 2008 Sep; 47(9):1384-8. PubMed ID: 18603660
    [Abstract] [Full Text] [Related]

  • 33. Dose escalation of infliximab therapy in arthritis patients is related to diagnosis and concomitant methotrexate treatment: observational results from the South Swedish Arthritis Treatment Group register.
    Kristensen LE, Geborek P, Saxne T.
    Rheumatology (Oxford); 2009 Mar; 48(3):243-5. PubMed ID: 19106164
    [Abstract] [Full Text] [Related]

  • 34. Combination treatment with infliximab and leflunomide in patients with active rheumatoid arthritis: safety and efficacy in an open-label clinical trial.
    Kalden JR, Nüsslein HG, Wollenhaupt J, Burmester GR, Krüger K, Antoni C.
    Clin Exp Rheumatol; 2008 Mar; 26(5):834-40. PubMed ID: 19032816
    [Abstract] [Full Text] [Related]

  • 35. Early and late effect of infliximab on circulating dendritic cells phenotype in rheumatoid arthritis patients.
    Balanescu A, Radu E, Nat R, Regalia T, Bojinca V, Ionescu R, Balanescu S, Savu C, Predeteanu D.
    Int J Clin Pharmacol Res; 2005 Mar; 25(1):9-18. PubMed ID: 15864873
    [Abstract] [Full Text] [Related]

  • 36. The SMILE study -- safety of methotrexate in combination with leflunomide in rheumatoid arthritis.
    Bird P, Griffiths H, Tymms K, Nicholls D, Roberts L, Arnold M, Burnet S, de Jager J, Scott J, Zochling J, Littlejohn G.
    J Rheumatol; 2013 Mar; 40(3):228-35. PubMed ID: 23322457
    [Abstract] [Full Text] [Related]

  • 37. Titration of infliximab treatment in rheumatoid arthritis patients based on response patterns.
    Flendrie M, Creemers MC, van Riel PL.
    Rheumatology (Oxford); 2007 Jan; 46(1):146-9. PubMed ID: 16782732
    [Abstract] [Full Text] [Related]

  • 38. Safety of leflunomide plus infliximab combination therapy in rheumatoid arthritis.
    Godinho F, Godfrin B, El Mahou S, Navaux F, Zabraniecki L, Cantagrel A.
    Clin Exp Rheumatol; 2004 Jan; 22(3):328-30. PubMed ID: 15144127
    [Abstract] [Full Text] [Related]

  • 39. Response-driven combination therapy with conventional disease-modifying antirheumatic drugs can achieve high response rates in early rheumatoid arthritis with minimal glucocorticoid and nonsteroidal anti-inflammatory drug use.
    Proudman SM, Keen HI, Stamp LK, Lee AT, Goldblatt F, Ayres OC, Rischmueller M, James MJ, Hill CL, Caughey GE, Cleland LG.
    Semin Arthritis Rheum; 2007 Oct; 37(2):99-111. PubMed ID: 17391739
    [Abstract] [Full Text] [Related]

  • 40. Efficacy and safety of leflunomide in DMARD-naive patients with early rheumatoid arthritis: comparison of a loading and a fixed-dose regimen.
    Cutolo M, Bolosiu H, Perdriset G, LEADER Study Group.
    Rheumatology (Oxford); 2013 Jun; 52(6):1132-40. PubMed ID: 23401601
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 37.